Siemens PETNET Solutions is expanding its imaging biomarker production capabilities in Nottingham, England, to include the ability to produce new biomarkers as investigational medicine products (IMP) in the U.K.

These IMPs include a proprietary hypoxic agent developed by Siemens for identification of tumor tissues with low oxygen supply, and an investigational amyloid agent, for PET imaging of beta-amyloid deposits in the brain, said the Knoxville, Tenn.-based PETNET.